Memphasys Secures European Felix Agreement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced a new exclusive distribution agreement for its Felix™ System in Europe, specifically covering the Czech Republic, Slovakia, and Kazakhstan. The agreement includes a minimum purchase commitment over three years, which is expected to increase as adoption of the Felix™ System grows. This partnership with INVIDO LAB aims to enhance Memphasys' commercial presence in established IVF markets and drive recurring revenue through single-use cartridges. The company has also strengthened its European operations by appointing a new director to lead commercial activities in the region.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Memphasys
- Memphasys Investor Webinar Presentation - September 2026
- Investor Webinar Invite
- Felix Registration Achieved in Turkey, Sales Commence
- Notification of cessation of securities - MEM
- EUR526,500 Nordic Agreement Expands Felix European Footprint
Later from Memphasys
- Application for quotation of securities - MEM
- Notification regarding unquoted securities - MEM
- Change of Director's Interest Notice
- Potential Expedited FDA Pathway to US IVF Market
- Proposed issue of securities - MEM
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys